GlycoMimetics Inc 2024年度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes ᶺNo ᶺ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes ᶺNo ᶺ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated FilerSmaller Reporting CompanyEmerging Growth Company Large Accelerated FilerNon-accelerated Filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ᶺ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness ofits internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered publicaccounting firm that prepared or issued its audit report. ᶺ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements. ᶺ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentiveᶺbasedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10Dᶺ1(b). ᶺ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes ᶺNo ᶺ As of June 30, 2024, the last business day of the registrant’s last completed second quarter, the aggregate market value of the CommonStock held by non-affiliates of the registrant was approximately $17.5 million based on the closing price of the registrant’s Common Stock, asreported by the Nasdaq Capital Market, on such date. At February 7, 2025, 64,513,862 shares of GlycoMimetics, Inc.’s Common Stock, $0.001 par value per share, were outstanding. DOCUMENTS INCORPORATED BY REFERENCE Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Actof 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-lookingstatements are contained principally in Part I, Item 1. “Business,” Part I, Item 1A. “Risk Factors,” and Part II,Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” but are alsocontained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words“may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,”“estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or othercomparable terminology intended to identify statements about the future. These statements involve known andunknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance orachievements to be materially different from the information expressed or implied by these forward-lookingstatements. Although we believe that we have a reasonable basis for each forward-looking statement contained inthis Annual Report, we caution you that these statements are based on a combination of facts and factors currentlyknown by us and our expectations of the future, about which we cannot be certain. Forward-looking statementsinclude statements about: ●our plans to consummate the proposed merger, or the Merger, between us and Crescent Biopharma,Inc.●the sufficiency of our cash resources to continue operating through consummation of the Merger;●our ability to maintain compliance with Nasdaq listing standards;●our plans to potentially explore other strategic alternatives or to dissolve or liquidate the Company ifthe Merger is not consummated;●the clinical utility of our drug candidates;●our potential commercialization, marketing and manufacturing capabilities